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ABSTRACT
Systemic mastocytoses represent neoplastic prolifera-
tions of mast cells. In about 20% of cases systemic
mastocytoses are accompanied by clonal haematopoietic
non-mast cell-lineage disorders, most commonly myeloid
neoplasms. A case of systemic mastocytosis carrying the
characteristic mutation at codon 816 (D816V) in the KIT
gene of mast cells, with two concurrent accompanying
clonal haematopoietic non-mast cell-lineage disorders,
chronic myeloproliferative disease, unclassifiable and
precursor B lymphoblastic leukaemia is documented. Both
accompanying clonal haematopoietic non-mast cell-line-
age disorders carried the wild-type KIT gene, but had a
novel t(13;13)(q12;q22) involving the FLT3 locus at
13q12. The chronic myeloproliferative disease, unclassifi-
able and the precursor B lymphoblastic leukaemia were
cured by syngenous stem cell transplantation, but the
systemic mastocytosis persisted for more than 10 years.
The additional impact of molecular techniques on the
correct diagnosis in haematological malignancies is
highlighted, and evidence is provided that, apart from
internal tandem duplications and mutations, FLT3 can be
activated by translocations.
Associated clonal haematopoietic non-mast cell-
lineage disorders (AHNMDs) can be observed in
about 20% of patients with systemic mastocytosis
(SM).1 2 SM and AHNMDs can be either clonally
related or not.3 4 Concurrent SM and precursor
lymphoblastic leukaemia (ALL) have not been
reported. Here, we describe a case of SM with
two AHNMDs, namely chronic myeloproliferative
disease, unclassifiable (CMPD, U) and B-ALL, both
AHNMDs carrying a novel t(13;13)(q12;q22)
involving the FLT3 locus.
MATERIALS AND METHODS
Histology
Bone marrow biopsy samples prior to 2000 were
fixed and decalcified in Susa’s medium, and after
2000 in 4% buffered formaldehyde solution and
EDTA; they were then embedded in paraffin.
Sections (3 mm) were stained with H&E, Giemsa
and Go¨mo¨ri stains.
Immunohistochemistry
Immunohistochemistry for CD3, CD10, CD20,
CD25, CD34, CD79a, CD117 and tryptase was
performed using an automated immunostainer
(Nexes, Ventana, USA), and for terminal deoxy-
nucleotidyl transferase (TdT) and phosphorylated
STAT5 manually.
Detection of the D816V mutation in the KIT gene
and the V617F mutation in the JAK2 gene
DNA from the bone marrow biopsy specimens
from 1996 and 2006 was evaluated for the KIT
mutation D816V by peptide nucleic acid-mediated
PCR-clamping and melting point analysis of the
products as described previously.5 DNA from
microdissected mast cells from 2006 and micro-
dissected lymphoblasts from 1996 was amplified
by nested PCR and analogously analysed for KIT
mutations.4 PCR for the JAK2 mutation V617F was
performed on bone marrow aspirates from 1995
and 2006 as described previously.6
Cytogenetic analysis and t(13;13)(q12;q22)
breakpoint mapping
Cell culture and chromosome preparations were
standard. Chromosomes were stained in G-bands.
To map the chromosomal breakpoints in
t(13;13)(q12;q22), the following bacterial artificial
chromosome probes were identified in the www.
genome.UCSC.edu database and obtained from
BACPAC Resources (Children’s Hospital, Oakland,
California,USA): RP11-94A1, RP11-274P12 (brid-
ging ZNF198 locus), RP11-80J14, RP11-367C11
(bridging FLT3 locus), RP11-87C7 (proximal
FLT3), RP11-85P8 (proximal/inside FLT3), RP11-
35M5 (distal/inside FLT3) and RP11-89P22 (distal
FLT3). Direct labelling of probes with FITC or Cy3
and metaphase fluorescence in situ hybridisation
(FISH) was standard. Interphase FISH with Cy3-
labelled RP11-87C7 and FITC-labelled RP11-35M5
was performed on bone marrow samples from the
initial diagnosis of SM-AHNMD (1996) and
persistent SM (2006) to determine the FLT3 status




In November 1995, a 46-year-old man was
admitted to our hospital with antiphlogistic
treatment-resistant bone pain, pruritus, raised
white blood cell count (16.16109/l) with increased
neutrophilic granulocytes (12.246109/l), eosinophi-
lia of 0.486109/l and monocytosis of 1.376109/l,
and splenomegaly of 17.5 cm, as assessed by
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ultrasonography. The leucocyte alkaline phosphatase index was
slightly decreased (15; normal range 20–100). Bone marrow
aspiration was dry tap. A trephine bone marrow biopsy
(fig 1A,B) showed hypercellularity of 95% with panmyelosis,
megakaryocytic dysplasia and focal clustering, eosinophilia of
10%, increased perisinusoidal mast cells with clustering and a
small paratrabecular population of CD20¡/TdT+/CD10¡
precursor B-cells (,2%). Reticulin fibres were increased corre-
sponding to myelofibrosis grade 1.7 The morphological changes
were considered consistent with CMPD, U with the possibility
of accompanying SM. Due to their low numbers and lack of
peripheral lymphocytosis the paratrabecular precursor B-cell
aggregates did not (even retrospectively) fulfil the minimal
requirements for ALL diagnosis. Conventional cytogenetic
analysis of the bone marrow samples from November 1995
(and a later overt B-ALL from March 1996) revealed a
t(13;13)(q12;q22) (fig 2A). Constitutional analysis (buccal
mucosa) showed normal karyotype. There were no BCR-ABL1
fusion products. Taking into consideration the clinical, imaging,
laboratory and morphological findings, the patient was diag-
nosed with CMPD and treated with hydroxycarbamide and
interferon a2a until severe leucopoenia required treatment
Figure 1 (A) Chronic myeloproliferative disorder, unclassified, diagnosed in 1995. Note hypercellularity, panmyelosis and atypical, partially clustering
megakaryocytes; H&E, 2006. (B) CD117 staining of the same biopsy. Note grouped, partially spindle-shaped, CD117+ mast cells, diagnostic for
systemic mastocytosis; immunoperoxidase, 2006. Insert: Analysis of the total DNA, extracted from the 1996 paraffin-embedded bone marrow biopsy
by peptide nucleic acid (PNA)-mediated PCR-clamping and melting point analysis revealed the KIT mutation D816V in the initial analysis (black
continuous line); black dotted line – without PNA-clamping. The mutation-specific melting peak is located at about 65uC, whereas the wild-type (wt)-
specific peak is located at about 59uC. Heterozygous control DNA (grey dotted line) showed nearly complete suppression of the wt signal after PCR-
clamping with a wt-specific PNA molecule (grey continuous line). (C) Precursor B lymphoblastic leukaemia (B-ALL) diagnosed in 1996. Sheets of blasts;
H&E. (D) TdT- and (E) CD79-expression in B-ALL; immunoperoxidase, 4006. (F) Slightly hypocellular routine 10-year post-transplant follow-up biopsy
from 2006; H&E, 2006. (G) CD117 staining of the same biopsy revealing increased amounts of mast cells; immunoperoxidase, 2006. Insert:
Amplification of total DNA from microdissected mast cells from the 2006 bone marrow biopsy by PNA-mediated PCR-clamping and melting point
analysis showed weak mutation-specific signals (black continuous lines; two small peaks at 65uC).
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discontinuation. Since he had a monozygous twin, syngenous
bone marrow transplantation was considered.
At the admission for graft procedures atypical lymphoid cells
were detected in the peripheral blood smear. Bone marrow
aspiration revealed hypercellularity as well as 50% precursor B-
cells with an aberrant flow cytometry-phenotype (CD19+/sIgM+/
CD34+/TdT+/CD10¡/CD20¡/CD22+/CD43+). Trephine bone
marrow biopsy revealed packed marrow with diffuse sheaths of
lymphoblasts, focally displacing the haematopoiesis, as well as
persistent mast cell hyperplasia and focal myeloproliferative
features (fig 1C–E). The lymphoblasts were immunohistochemi-
cally CD20¡/CD79a+/CD34+/TdT+/CD10¡. B-ALL with reac-
tive mast cell hyperplasia was diagnosed. The patient was treated
with chemotherapy consisting of dexamethasone, vincristine,
ifosphamide, carboplatin and etoposide followed by conditioning
with etoposide and cyclophosphamide prior to total body
irradiation and syngenous peripheral stem cell transplantation.
Complete haematological remission to the last control examina-
tion in April 2008 was achieved.
In the follow-up period from 1996 to 2001, the patient
complained of hyperpigmentation, relapsing pruritus, rashes,
intermittent diarrhoea, and poor circulation in his fingertips.
The routine 3-, 6- and 12-month post-transplant biopsies
showed complete remission of B-ALL and CMPD, U and
persistent minor mast cell hyperplasia. A routine 10-year
follow-up trephine bone marrow biopsy in August 2006 was
normocellular, with persistent complete morphological remis-
sion of B-ALL and CMPD, U. An increased amount of
perivascular, focally-grouped mast cells was detected (fig 1F,G).
These mast cells were tryptase+/CD117+/CD25+, indicating a
neoplastic phenotype.
Genetic analysis
Dual-colour metaphase FISH carried out in 2007 on archived
bone marrow cells from 1996 pointed to the involvement of the
FLT3 gene in the t(13;13)(q12;q22) (fig 2B; localised in the
proximal gene part). Only the bone marrow probe from 2006
was evaluable for interphase FISH. Breaks involving FLT3 could
not be detected in 50 identifiable mast cells or 200 additional
haemopoietic cells.
To study the functional consequences of the FLT3 rearrange-
ment, the phosphorylation status of its downstream target,
STAT5,8 was immunohistochemically analysed and compared
to other acute leukaemia cases without FLT3 abnormalities
(data not shown). Nuclear phosphorylated STAT5 was detect-
able in 20% of B-ALL cells of the present case (fig 2B, insert), but
not in blasts of acute leukaemias without FLT3 abnormalities.
DNA analysis showed the KIT mutation D816V in the initial
bone marrow biopsy from 1996 only with peptide nucleic acid-
mediated PCR-clamping (fig 1A, insert) and in microdissected
mast cells from the bone marrow biopsy in 2006 (fig 1G, insert).
In contrast, the mutation was not detected in microdissected
lymphoblasts from the bone marrow biopsy in 1996. JAK2 was
wild-type.
Final integrative interpretation considering molecular analyses
Taking into consideration the presence of three minor criteria
(.25% spindle-shaped mast cells, co-expression of CD117 and
CD25, and KIT mutation D816V, but normal serum tryptase,
assessed only in 2006)1 and all other molecular findings, the
integrative diagnosis of persistent indolent SM with complete
remission of the coexistent AHNMDs (CMPD, U and B-ALL)
was finally established in 2006.
DISCUSSION
SMs in SM-AHNMDs are most commonly accompanied by
myeloid malignancies and rarely by lymphoproliferative dis-
orders, but thus far association with ALL has not been
documented.2 Importantly, clonal relationship between SM
and AHNMD is currently not required to classify a coincidental
haematological malignancy as AHNMD; if SM diagnosis is
established, any accompanying haematological malignancy
should be classified as AHNMD.1 The observed co-occurrence
of SM and ALL in our patient may be related to a possible
lymphoblastic transformation (blast phase) of the initial
CMPD, U. This assumption is supported by the clinical
Figure 2 Cytogenetic results. (A) G-banded karyotype:
46,XY,t(13;13)(q12;q22). (B) Dual-colour metaphase fluorescence in situ
hybridisation with RP11-85P8- (Cy3, red) and RP11-35M5 probes (FITC,
green) showing a small red signal on the short der(13) and two fusion
signals on the long der(13)(DAPI counterstaining). Insert: nuclear
phosphorylated STAT5 expression in B-ALL cells from 1996 (anti-
phospho-STAT5 antibody from Cell Signaling (Boston, Massachusetts,
USA); dilution: 1:50, antigen retrieval: microwave, 100uC/15 min, citrate
buffer pH 6).
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chronology as well as by the detection of the t(13;13)(q12;q22)
in both aspirates from 1995 (CMPD, U) and 1996 (B-ALL).
Importantly, mast cells of SM did not carry t(13;13)(q12;q22),
whereas B-ALL and CMPD, U did not carry the KIT mutation
D816V, which is highly suggestive of differential clonal origins
of SM and AHNMDs.
Regarding the novel t(13;13)(q12;q22), our observations
imply that FLT3 can be activated not only by internal tandem
duplications and mutations8 but also by translocations as in the
case of another tyrosin kinase-encoding oncogene JAK2.9
Although investigated on a single case, this assumption is
further supported by the higher amount of phosphorylated
STAT5 (flt3 downstream target)8 in B-ALL cells in the index
(fig 2B, insert) compared to reference cases (data not shown). In
line with this hypothesis, a CMPD case with hypereosinophilia
and t(12;13)(p13;q12) leading to FLT3/ETV6 fusion has been
reported,10 thereby clearly demonstrating the oncogenic poten-
tial of dimerisable chimeric flt3.
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Take-home messages
c Systemic mastocytosis can be accompanied by precursor cell
lymphoblastic leukaemia.
c In addition to internal tandem duplications and mutations, FLT3
can be activated by translocations.
c Systemic mastocytosis might be resistant to stem
transplantation and persist after eradication of associated
clonal haematopoietic non-mast cell-lineage disorders.
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